Low coverage of central point vaccination against dog rabies in Bamako, Mali (Publications)
Canine rabies remains an important public-health problem in Africa. Dog mass vaccination is the recommended method for rabies control and elimination. We report on the first small-scale mass dog vacci
The lipid-modifying enzyme SMPDL3B negatively regulates innate immunity (Publications)
Lipid metabolism and receptor-mediated signaling are highly intertwined processes that cooperate to fulfill cellular functions and safeguard cellular homeostasis. Activation of Toll-like receptors (TL
Using lung cancer mortality to indirectly approximate smoking patterns in space (Publications)
Smoking is the leading cause of lung cancer. Non-smoking factors have been associated with the disease. Existing Swiss survey data only capture the country partially and temporal coverage does not all
Antiviral innate immune activation in HIV infected adults negatively affects H1/IC31(R) induced vaccine-specific memory CD4+ T cells (Publications)
Tuberculosis (TB) remains a global health problem, with vaccination being a necessary strategy for disease containment and elimination. A TB vaccine should be safe and immunogenic as well as efficacio
Civil registration and vital statistics: progress in the data revolution for counting and accountability (Publications)
New momentum for civil registration and vital statistics (CRVS) is building, driven by the confluence of growing demands for accountability and results in health, improved equity, and rights-based app
Human African trypanosomiasis prevention, treatment and control costs: a systematic review (Publications)
The control and eventual elimination of human African trypanosomiasis (HAT) requires the expansion of current control and surveillance activities. A systematic review of the published literature on th
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3,... (Publications)
BACKGROUND: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, i